CIK 0001023024 · Large accelerated filer
ANI PHARMACEUTICALS INC
Sign in to watch- Ticker
- ANIP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 582301143
- Phone
- 6097591810
- Business address
- 104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, NJ, 08540
- Former names
- BIOSANTE PHARMACEUTICALS INC, BEN ABRAHAM TECHNOLOGIES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,939,756
- in 9 filings, $1.9M under 10b5-1 plans
Net −$1,939,756. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-14 | Gutwerg Ori SVP, GENERICS | Grant or award | +9,842 | 85,520 | ||
| 2024-02-14 | Lalwani Nikhil PRESIDENT & CEO | Grant or award | +80,530 | 430,274 | ||
| 2024-02-14 | Lalwani Nikhil PRESIDENT & CEO | Grant or award | +53,686 | 483,960 | ||
| 2024-02-14 | CAREY STEPHEN P. SVP & CFO | Grant or award | +21,474 | 177,313 | ||
| 2024-02-14 | CAREY STEPHEN P. SVP & CFO | Grant or award | +14,316 | 191,629 | ||
| 2024-02-14 | Marken James G. SVP OPS & PROD DEV | Grant or award | +10,066 | 143,178 | ||
| 2024-02-14 | Marken James G. SVP OPS & PROD DEV | Grant or award | +6,710 | 149,888 | ||
| 2024-02-13 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale 10b5-1 | −250 | $56.04 | $14K | 36,799 |
| 2024-01-23 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −15,000 | $56.44 | $847K | 882,620 |
| 2024-01-22 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −5,692 | $55.95 | $318K | 897,620 |
| 2024-01-19 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −4,524 | $55.57 | $251K | 903,312 |
| 2024-01-18 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −9,784 | $55.30 | $541K | 907,836 |
| 2024-01-17 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −10,000 | $55.11 | $551K | 917,620 |
| 2024-01-16 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −5,000 | $55.63 | $278K | 927,620 |
| 2024-01-12 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale 10b5-1 | −250 | $56.43 | $14K | 37,049 |
| 2023-12-19 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −25,000 | $52.65 | $1.3M | 932,620 |
| 2023-12-18 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −13,026 | $52.44 | $683K | 957,620 |
| 2023-12-15 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −11,974 | $52.44 | $628K | 970,646 |
| 2023-12-11 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale 10b5-1 | −250 | $49.21 | $12K | 37,299 |
| 2023-11-17 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −13,000 | $51.00 | $663K | 982,620 |
Page 16 of 23 · 442 trades